PMID- 36494293
OWN - NLM
STAT- MEDLINE
DCOM- 20230214
LR  - 20230215
IS  - 1871-403X (Print)
IS  - 1871-403X (Linking)
VI  - 17
IP  - 1
DP  - 2023 Jan-Feb
TI  - Naringin reduces fat deposition by promoting the expression of lipolysis and 
      beta-oxidation related genes.
PG  - 74-81
LID - S1871-403X(22)00129-6 [pii]
LID - 10.1016/j.orcp.2022.11.004 [doi]
AB  - AIMS: Naringin, a flavonoid present in citrus fruits, has been known for the 
      capacity to reduce lipid synthesis and anti-inflammatory. In this study, we 
      investigated whether naringin increases lipolysis and fatty acid beta-oxidation to 
      change fat deposition. METHODS: In in vivo experiment, obese adult mice 
      (20-weeks-old, n = 18) were divided into control group fed with normal diet and 
      naringin-treated group fed with naringin-supplemented diet (5 g/kg) for 60 days, 
      respectively. In in vitro experiment, differentiated 3T3-L1 adipocytes were 
      treated for four days with or without naringin (100 microg/mL). RESULTS: 
      Supplementing naringin significantly reduced the body weight, abdominal fat 
      weight, blood total cholesterol content of mice, but did not affect food intake. 
      In addition, naringin decreased levels of pro-inflammatory factors in adipose 
      tissue including interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and monocyte 
      chemotactic protein 1 (MCP-1). Naringin increased the expression of AMP-activated 
      protein kinase (AMPK), a key factor in cellular energy metabolism, and raised the 
      ratio of p-AMPK/AMPK in mouse liver tissue. The protein expression of 
      hormone-sensitive lipase (HSL), phospho-HSL563 (p-HSL563), p-HSL563/HSL, and 
      adipocyte triglyceride lipase (ATGL) was significantly increased in the adipose 
      tissue of naringin-treated mice. Furthermore, naringin enhanced the expression of 
      fatty acid beta-oxidation genes, including carnitine palmitoyl transferase 1 (CPT1), 
      uncoupling protein 2 (UCP2), and acyl-coenzyme A oxidase 1 (AOX1) in mouse 
      adipose tissue. In in vitro experiment, similar findings were observed in 
      differentiated 3T3-L1 adipocytes with naringin treatment. The treatment 
      remarkably reduced intracellular lipid content, increased the number of 
      mitochondria and promoted the gene expression of HSL, ATGL, CPT1, AOX1, and UCP2 
      and the phosphorylation of HSL protein. CONCLUSION: Naringin reduced body fat in 
      obese mice and lipid content in differentiated 3T3-L1 adipocytes, which was 
      associated with enhanced AMPK activation and upregulation of the expression of 
      the lipolytic genes HSL, ATGL, and beta-oxidation genes CPT1, AOX1, and UCP2.
CI  - Copyright (c) 2022 Asia Oceania Association for the Study of Obesity. Published by 
      Elsevier Ltd. All rights reserved.
FAU - Wang, Jing
AU  - Wang J
AD  - Chongqing Academy of Animal Science, Chongqing, PR China.
FAU - Wang, Qi
AU  - Wang Q
AD  - Chongqing Academy of Animal Science, Chongqing, PR China.
FAU - Zhu, Siyuan
AU  - Zhu S
AD  - Southwest University of Science and Technology, Sichuan, PR China.
FAU - Huang, Jinxiu
AU  - Huang J
AD  - Chongqing Academy of Animal Science, Chongqing, PR China.
FAU - Liu, Zuohua
AU  - Liu Z
AD  - Chongqing Academy of Animal Science, Chongqing, PR China. Electronic address: 
      liuzuohua66@163.com.
FAU - Qi, Renli
AU  - Qi R
AD  - Chongqing Academy of Animal Science, Chongqing, PR China. Electronic address: 
      qirenli1982@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221207
PL  - Netherlands
TA  - Obes Res Clin Pract
JT  - Obesity research & clinical practice
JID - 101303911
RN  - N7TD9J649B (naringin)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
RN  - EC 3.1.1.13 (Sterol Esterase)
RN  - EC 3.1.1.3 (Lipase)
RN  - 0 (Fatty Acids)
RN  - 0 (Lipids)
SB  - IM
MH  - Mice
MH  - Animals
MH  - *Lipolysis
MH  - *AMP-Activated Protein Kinases/metabolism
MH  - Sterol Esterase/metabolism
MH  - Lipase
MH  - Fatty Acids
MH  - Lipids
MH  - 3T3-L1 Cells
OTO - NOTNLM
OT  - Differentiated 3T3-L1 adipocytes
OT  - Fatty acid beta-oxidation
OT  - Lipolysis
OT  - Naringin
OT  - Obese mice
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/12/10 06:00
MHDA- 2023/02/15 06:00
CRDT- 2022/12/09 22:08
PHST- 2021/03/13 00:00 [received]
PHST- 2022/11/17 00:00 [revised]
PHST- 2022/11/21 00:00 [accepted]
PHST- 2022/12/10 06:00 [pubmed]
PHST- 2023/02/15 06:00 [medline]
PHST- 2022/12/09 22:08 [entrez]
AID - S1871-403X(22)00129-6 [pii]
AID - 10.1016/j.orcp.2022.11.004 [doi]
PST - ppublish
SO  - Obes Res Clin Pract. 2023 Jan-Feb;17(1):74-81. doi: 10.1016/j.orcp.2022.11.004. 
      Epub 2022 Dec 7.